Literature DB >> 22955914

Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.

Enrico Tiacci1, Claudia Döring, Verena Brune, Carel J M van Noesel, Wolfram Klapper, Gunhild Mechtersheimer, Brunangelo Falini, Ralf Küppers, Martin-Leo Hansmann.   

Abstract

The pathogenesis of classical Hodgkin lymphoma (cHL), the most common lymphoma in the young, is still enigmatic, largely because its Hodgkin and Reed-Sternberg (HRS) tumor cells are rare in the involved lymph node and therefore difficult to analyze. Here, by overcoming this technical challenge and performing, for the first time, a genome-wide transcriptional analysis of microdissected HRS cells compared with other B-cell lymphomas, cHL lines, and normal B-cell subsets, we show that they differ extensively from the usually studied cHL cell lines, that the lost B-cell identity of cHLs is not linked to the acquisition of a plasma cell-like gene expression program, and that Epstein-Barr virus infection of HRS cells has a minor transcriptional influence on the established cHL clone. Moreover, although cHL appears a distinct lymphoma entity overall, HRS cells of its histologic subtypes diverged in their similarity to other related lymphomas. Unexpectedly, we identified 2 molecular subgroups of cHL associated with differential strengths of the transcription factor activity of the NOTCH1, MYC, and IRF4 proto-oncogenes. Finally, HRS cells display deregulated expression of several genes potentially highly relevant to lymphoma pathogenesis, including silencing of the apoptosis-inducer BIK and of INPP5D, an inhibitor of the PI3K-driven oncogenic pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955914     DOI: 10.1182/blood-2012-05-428896

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma.

Authors:  L Dimitrova; V Seitz; J Hecht; D Lenze; P Hansen; M Szczepanowski; L Ma; E Oker; A Sommerfeld; F Jundt; W Klapper; M Hummel
Journal:  Leukemia       Date:  2013-07-11       Impact factor: 11.528

2.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

3.  Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells.

Authors:  Marc A Weniger; Enrico Tiacci; Stefanie Schneider; Judith Arnolds; Sabrina Rüschenbaum; Janine Duppach; Marc Seifert; Claudia Döring; Martin-Leo Hansmann; Ralf Küppers
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

Review 4.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

5.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Erik Ladewig; Gianluca Schiavoni; Alex Penson; Elisabetta Fortini; Valentina Pettirossi; Yuchun Wang; Ariele Rosseto; Alessandra Venanzi; Sofija Vlasevska; Roberta Pacini; Simonetta Piattoni; Alessia Tabarrini; Alessandra Pucciarini; Barbara Bigerna; Alessia Santi; Alessandro M Gianni; Simonetta Viviani; Antonello Cabras; Stefano Ascani; Barbara Crescenzi; Cristina Mecucci; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  Blood       Date:  2018-04-12       Impact factor: 22.113

6.  WNT5A: a motility-promoting factor in Hodgkin lymphoma.

Authors:  F Linke; S Zaunig; M M Nietert; F von Bonin; S Lutz; C Dullin; P Janovská; T Beissbarth; F Alves; W Klapper; V Bryja; T Pukrop; L Trümper; J Wilting; D Kube
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

7.  The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells.

Authors:  K Ullrich; F Blumenthal-Barby; B Lamprecht; K Köchert; D Lenze; M Hummel; S Mathas; B Dörken; M Janz
Journal:  Leukemia       Date:  2014-12-09       Impact factor: 11.528

8.  BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Authors:  S L Locatelli; L Cleris; G G Stirparo; S Tartari; E Saba; M Pierdominici; W Malorni; A Carbone; A Anichini; C Carlo-Stella
Journal:  Leukemia       Date:  2014-02-24       Impact factor: 11.528

9.  Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.

Authors:  Stephen J Salipante; Andrew Adey; Anju Thomas; Choli Lee; Yajuan J Liu; Akash Kumar; Alexandra P Lewis; David Wu; Jonathan R Fromm; Jay Shendure
Journal:  Genes Chromosomes Cancer       Date:  2015-12-09       Impact factor: 5.006

Review 10.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.